Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Pain 19Neoplasms 17Cancer Pain 15Pain, Postoperative 12Agnosia 8Chronic Pain 7Neoplasm Metastasis 4Head and Neck Neoplasms 4Colorectal Neoplasms 4Colonic Neoplasms 4Breast Neoplasms 4Multiple Myeloma 3Mucositis 3Lymphoma, Follicular 3Lymphoma 3Leukemia, Myeloid, Acute 3Leukemia, Biphenotypic, Acute 3Leukemia 3Wounds and Injuries 2Waldenstrom Macroglobulinemia 2Thrombocythemia, Essential 2Supratentorial Neoplasms 2Sezary Syndrome 2Primary Myelofibrosis 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Precancerous Conditions 2Polycythemia Vera 2Pdgfra-Associated Chronic Eosinophilic Leukemia 2Pancreatic Neoplasms 2

Interventions

Nalbuphine 1Morphine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Nalbuphine Allergy × Morphine × Clear all
NCT05073744 2022-12-29

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Zhongda Hospital

Phase 4 Unknown
316 enrolled

Nalbuphine Allergy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡